等待开盘 03-27 09:30:00 美东时间
-0.110
-0.14%
In addition, Apogee expects to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
03-24 04:02
Dow up 2.45%, Nasdaq up 2.46%, S&P 500 up 2.19%. Consumer discretionary shares up 3.6%, energy stocks up 0.3%. Dell announces enhancements, BofA raises price target. Apogee up 17%, Tower Semi up 9%, Urban-gro up 46%. Atlantic Int'l down 13%, Linkers down 85%, Valneva down 37%. Oil down 8.1%, gold down 2.1%. European and Asian markets mixed.
03-24 03:15
Apogee Therapeutics stock jumps on 52-week eczema data; durable response supports Phase 3 plans later in 2026.
03-23 22:04
Apogee Therapeutics (NASDAQ:APGE) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.04) by 1.25 percent. This is a 13.45 percent increase over losses of $(1.19) per share
03-02 20:27
08:43 AM EDT, 08/19/2024 (MT Newswires) -- Apogee Therapeutics (APGE) said Monday it has dosed the first participants for the phase 1 trial of APG990, the company's investigative subcutaneous treatment for atopic dermatitis. Apogee said it expects interim data from the trial in 2025. Shares of the c...
2024-08-19 20:43